EGFR and neoplasm: Activating mutations in epidermal growth factor receptor (EGFR) sensitize the majority of non-small cell lung cancer (NSCLC) tumours harbouring these lesions to EGFR tyrosine kinase inhibitors (TKIs)1, 2, 3.